A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose
limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced
lymphoid malignancies.